Wellington Management Group LLP cut its position in shares of Zenas Biopharma Inc (NASDAQ:ZBIO - Free Report) by 24.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,135,289 shares of the company's stock after selling 366,139 shares during the quarter. Wellington Management Group LLP owned about 2.72% of Zenas Biopharma worth $9,172,000 as of its most recent filing with the Securities & Exchange Commission.
Analyst Ratings Changes
Several equities research analysts recently weighed in on ZBIO shares. Wedbush restated an "outperform" rating and set a $35.00 price target on shares of Zenas Biopharma in a research report on Thursday, May 15th. HC Wainwright restated a "buy" rating and set a $30.00 price target on shares of Zenas Biopharma in a research report on Friday, May 16th. Finally, Guggenheim restated a "buy" rating and set a $45.00 price target on shares of Zenas Biopharma in a research report on Wednesday, March 12th.
Get Our Latest Analysis on Zenas Biopharma
Zenas Biopharma Price Performance
NASDAQ:ZBIO traded up $1.51 during trading hours on Friday, reaching $11.12. 197,971 shares of the company traded hands, compared to its average volume of 181,254. The firm has a 50-day moving average price of $9.52. The firm has a market capitalization of $465.19 million and a PE ratio of -3.13. Zenas Biopharma Inc has a 1 year low of $5.83 and a 1 year high of $26.25.
Zenas Biopharma (NASDAQ:ZBIO - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.15) by $0.35. The company had revenue of $10.00 million for the quarter, compared to analysts' expectations of $5.00 million.
Zenas Biopharma Profile
(
Free Report)
Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
Featured Stories
Before you consider Zenas BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zenas BioPharma wasn't on the list.
While Zenas BioPharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
